CONTACT
+91 80 2808 2808
info@biocon.com

News - Posts

Biocon  /  News – Posts

Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World

  • Posted by: BIOCON

Biocon Biologics’ Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)

  • Posted by: BIOCON

Biocon Pharma Limited Receives U.S. FDA Approval for Tofacitinib Extended-Release Tablets

  • Posted by: BIOCON

Kiran Mazumdar-Shaw Ranked Among India’s Most Generous Women Philanthropists by EdelGive Hurun India Philanthropy List 2025

  • Posted by: BIOCON

Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%;

  • Posted by: BIOCON

Company Statement on Biocon’s Visakhapatnam API Facility (Site 6)

  • Posted by: BIOCON

Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®

  • Posted by: BIOCON

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options

  • Posted by: BIOCON

Company Statement on Biocon’s Cranbury, New Jersey Manufacturing Site

  • Posted by: BIOCON

Biocon Pharma Limited Secures U.S. FDA Tentative Approval for Rifaximin Tablets in Partnership with Carnegie Pharmaceuticals

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>